Early detection and intervention using neutrophil gelatinase-associated lipocalin (NGAL) may improve renal outcome of acute contrast media induced nephropathy: A randomized controlled trial in patients undergoing intra-arterial angiography (ANTI-CIN Study) by Schilcher, Gernot et al.
STUDY PROTOCOL Open Access
Early detection and intervention using neutrophil
gelatinase-associated lipocalin (NGAL) may
improve renal outcome of acute contrast media
induced nephropathy: A randomized controlled
trial in patients undergoing intra-arterial
angiography (ANTI-CIN Study)
Gernot Schilcher
1, Werner Ribitsch
1, Ronald Otto
1, Rupert H Portugaller
2, Franz Quehenberger
3,
Martini Truschnig-Wilders
4, Robert Zweiker
5, Philipp Stiegler
6, Marianne Brodmann
7, Klemens Weinhandl
1 and
Joerg H Horina
1*
Abstract
Background: Patients with pre-existing impaired renal function are prone to develop acute contrast media
induced nephropathy (CIN). Neutrophil gelatinase-associated lipocalin (NGAL), a new biomarker predictive for acute
kidney injury (AKI), has been shown to be useful for earlier diagnosis of CIN; however, urinary NGAL values may be
markedly increased in chronic renal failure at baseline. Results from those studies suggested that urinary NGAL
values may not be helpful for the clinician. An intravenous volume load is a widely accepted prophylactic measure
and possibly a reasonable intervention to prevent deterioration of renal function. The aim of our study is to
evaluate NGAL as an early predictor of CIN and to investigate the clinical benefit of early post-procedural i.v.
hydration.
Methods/Design: The study will follow a prospective, open-label, randomized controlled design. Patients requiring
intra-arterial contrast media (CM) application will be included and receive standardized, weight-based, intravenous
hydration before investigation. Subjects with markedly increased urinary NGAL values after CM application will be
randomized into one of two study groups. Group A will receive 3-4 ml/kg BW/h 0.9% saline intravenously for 6
hours. Group B will undergo only standard treatment consisting of unrestricted oral fluid intake. The primary
outcome measure will be CIN defined by an increase greater than 25% of baseline serum creatinine. Secondary
outcomes will include urinary NGAL values, cystatin C values, contrast media associated changes in cardiac
parameters such as NT-pro-BNP/troponin T, changes in urinary cytology, need for renal replacement treatment,
length of stay in hospital and death.
We assume that 20% of the included patients will show a definite rise in urinary NGAL. Prospective statistical
power calculations indicate that the study will have 80% statistical power to detect a clinically significant decrease
of CIN of 40% in the treatment arm if 1200 patients are recruited into the study.
Discussion: A volume expansion strategy showing a benefit from earlier intervention for patients with markedly
elevated urinary NGAL values, indicating a CIN, might arise from data from this study.
Trial registration: ClinicalTrials.gov NCT01292317
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In recent decades, the growing demand for sophisticated
diagnostics in all fields of modern medicine has
increased the need for contrast-enhanced imaging [1].
The amount of iodinated contrast media (CM) used
worldwide cannot be even roughly estimated. While
contrast-enhanced procedures are fairly safe in the
healthy population, patients with pre-existing impaired
renal and/or cardiac function are prone to develop acute
kidney injury (AKI) due to acute contrast induced
nephropathy (CIN) and so have a greater risk of death
[2,3]. This has been shown in patients undergoing cor-
onary angiography and intervention who sometimes end
up with end-stage renal disease [4,5]. The effect of an
immediate post-procedural hemodialysis treatment to
eliminate CM load is also discussed controversially [6,7].
Until recently and for this reason, physicians have
increasingly used gadolinium enhanced magnetic reso-
nance imaging to avoid renal complications, especially
in such high-risk patients. For interventional settings,
however, gadolinium enhanced magnetic resonance ima-
ging has never been an appropriate alternative.
Also, with the recognition of nephrogenic systemic
sclerosis as a severe and also life-threatening gadolinium
side effect without treatment options, physicians now
have to weigh the risk of either investigation for the
individual patient [8,9]. A return to iodinated CM
enhanced investigations is now seen in many clinical
settings.
A variety of investigators have tried to establish risk
scores for patients before investigation [10,11]. To date,
a reliable laboratory value or test that recognizes acute
renal damage before serum creatinine increases is still
being sought and might be a most helpful tool to initiate
proper treatment on time. Neutrophil gelatinase-asso-
ciated lipocalin (NGAL), a new biomarker predictive for
acute renal injury, has been shown to be capable of ear-
lier diagnosis in patients undergoing cardiac surgery and
CIN [12-16]. NGAL so might be the desired diagnostic
link between acute kidney damage and the later occur-
rence of elevated creatinine values. Randomized con-
trolled trials using this “timesaver” for earlier
intervention have not yet been performed, but would be
highly desirable [17]. Such a study might change physi-
cians’ therapeutic strategies and improve clinical
outcomes.
One major drawback of this new biomarker may be
t h ef a c tt h a to n l yl i t t l ei sk n o w na b o u ti t sv a l u ea n d
accuracy in patients with underlying chronic kidney dis-
ease (CKD), and a predictive pattern or cut-off level in
patients developing “acute on chronic renal failure” has
not yet been defined. Some investigators found markedly
increased NGAL levels in individual patients, far above
the proposed cut-offs for acute renal failure. They also
discovered a significant inverse relation between NGAL
and renal function defined by glomerular filtration rate
(GFR) [18,19]. Mori et al. have speculated that con-
stantly increased, yet stable NGAL values in CKD are
the consequences of sustained production by “inflamed”,
but vital tubular cells [20]. Even more complicating is
the fact that age and several co-morbidities, such as
inflammation and chronic heart disease, common in
patients with chronic renal failure, may also influence
NGAL levels [21,22]. A meta-analysis by Haase et al.
selected 19 relevant published articles and defined 150
ng/ml as a possible cut-off value with a proper sensitiv-
ity and specificity [23]. This analysis also confirmed a
comparable accuracy of plasma and urinary NGAL,
whereas urinary NGAL testing may be even better in
patients with CKD [24].
So far, an intravenous volume load is the only reason-
ably proven and widely accepted prophylaxis for CIN
after CM application [25-28]. In the majority of the rele-
vant randomized controlled trials, isotonic saline infu-
sion (0.9%) was used for volume expansion, while some
authors used half-isotonic saline (0.45%) or sodium
bicarbonate at higher volumes. The benefit of this type
of intervention is not a pharmacologic effect of a speci-
fic type of infusion, but rather a physical effect of
volume expansion. The optimal intravenous fluid regi-
men regarding the type, amount, route and duration of
volume application remains controversial.
Hydration regimens have differed widely among rele-
vant randomized trials and so are not comparable [29].
Further, most studies also lacked statistical power, used
different types of CM and definitions of CIN or allowed
for additional prophylactic measures, such as N-acetyl-
cysteine or sodium bicarbonate in a varying percentage
of their patients [30-38].
Worldwide, there are no generally accepted guidelines
for a controlled and standardized prophylactic volume
application among radiologists, cardiologists, nephrolo-
gists and other involved physicians. In other words, the
beneficial effect of intravenous hydration is not used to
greatest advantage.
In our study, all patients requiring intra-arterial CM
application will receive a weight-based, standardized
intravenous hydration before investigation. This measure
of controlled pre-hydration alone might be of great ben-
efit for our patients and differs from routine clinical
practice, where patients often only receive oral fluid at
best. To date, intravenous hydration is not even an
established clinical standard for the so-called “high-risk
patient” with e.g. diabetes and/or renal failure.
A randomized trial evaluating the clinical benefit of
additional post-procedural i.v. hydration might provide a
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practice.
Controlled post-procedural i.v. hydration has not been
used consistently for several reasons [29]:
(a) worldwide, a large percentage of CM studies are
performed on an outpatient basis;
(b) there are no clear data proving the benefit of addi-
tional post-procedural i.v. hydration, versus pre-proce-
dural hydration only;
(c) intravenous hydration, both pre- and post-proce-
dural, is often not performed for organizational reasons.
Rationale and hypothesis
Earlier detection of CIN by the novel urinary NGAL test
method enables amelioration of renal injury by the
introduction of rapid and intensified post-procedural
(angiography) volume expansion.
Aims of our study
1). To evaluate the true risk of CIN in high-risk
patients following intra-arterial angiography using a
standardized pre-procedural protocol for intravenous
volume load.
2). To evaluate the benefit of an earlier diagnosis of
renal damage after investigation using urinary
NGAL.
3). To investigate the effect of a well-timed and
intensified post-procedural volume expansion on
renal function, morbidity and mortality in patients
predicted to develop CIN according to NGAL
testing.
4). To study NGAL in patients with mild, moderate
and severe CKD (stage 2-4), a subgroup of indivi-
duals who frequently develop CIN. At present it is
still unclear whether the new biomarker NGAL is
comparably effective in this particular group.
5). To define and establish a reliable cut-off value or
pattern of increase for NGAL in patients with
chronic renal failure and to estimate its sensitivity
and specificity.
6). To assess the value of a 25% increase in serum
creatinine as a definition for clinically relevant CIN.
7). To compare the value of NGAL and cystatin C in
predicting CIN.
8). To compare the value of the MDRD, the CKD-
EPI- and the Cockcroft-Gault formula in this parti-
cular patient group.
At this stage, little is known about the beneficial effect
of earlier diagnosis and subsequent intervention by
volume expansion on AKI due to a rise in urinary NGAL.
A st h et i m ec o u r s eo fk i d n e yd a m a g ei su s u a l l yn o t
apparent, contrast media induced nephropathy (CIN) is a
promising condition for this question. Results from
previous studies are unable to guide the clinician when
baseline urinary NGAL levels exceed the normal range.
T oo u rk n o w l e d g e ,t h i si st he first clinical study to
address this problem. We are trying to assess the effect
of an early intervention by volume expansion in patients
with increasing urinary NGAL levels 4-6 hours following
CM application. If a significant reduction of CIN as
defined by creatinine levels is found in the treatment
arm within 2 days, a clear benefit of measuring urinary
NGAL might be postulated. We are currently recruiting
patients for this non-commercial investigator initiated
trial to elucidate CIN.
Methods and design
Study Design and Setting
This study is a single center, open label, randomized
controlled trial involving subjects undergoing an intra-
arterial angiographic procedure with iodinated CM. The
study is being conducted at the University Hospital in
Graz, Austria.
Ethical considerations
The Ethics Committee of the Medical University of
Graz, Austria, approved this trial (Registration Number:
21-278 ex 09/10). The Ethics Committees will be pro-
vided with annual reports of trial progress and will
promptly receive all adverse event reports. Participants
may declare their withdrawal at any time during the
study.
Participants
Patients scheduled for diagnostic intra-arterial catheter
angiography or endovascular intervention will be invited
to participate in the study. Only one type of iso-osmolar,
non-ionic, monomeric CM (Iomeron
®) will be used. The
most common underlying diseases in these individuals
are coronary heart disease, peripheral arterial occlusive
disease and renal artery stenosis.
Identification of eligible patients
The principle investigator and the clinical trial coordina-
tors will screen the medical records of patients for pre-
existing renal failure one day prior to an angiographic
intervention at the Divisions of Nephrology, Cardiology,
Angiology and Radiology at the University Hospital in
Graz, Austria. Eligible patients will have a copy of the
patient information sheet placed in the medical record.
The investigator will explain the study during the clini-
cal consultation. Only subjects giving written informed
consent will be included. The study period will last 4
days, starting one day prior to investigation and ending
two days after the intra-arterial angiography (Figure 1).
A one year follow up consultation is targeted. All
patients with CIN will be followed separately.
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￿ Patients requiring intra-arterial angiography/
angioplasty
￿ Patients older than 18 years
￿ Patients with clinically stable CKD of stage 2 or
more (calculated GFR < 70 ml/min/1,73 m2)(65)
￿ Gender: both
￿ Written informed consent
Exclusion criteria
￿ Pre-existing clinical and/or laboratory evidence of
acute renal failure at the time of enrolment
￿ Evidence of rhabdomyolysis
   
Identification of eligible patients: 
 
     - Patients scheduled for intra-arterial angiography/angioplasty 
day -1   - Estimated glomerular filtration rate (MDRD) < 70ml / min / 1,73 m
2 
    - Ability to provide informed consent 
 
    Laboratory values: 
 Baseline creatinine, complete blood count, etc., and urinary NGAL 
 
 
       
 
    Standardized pre-interventional i.v. hydration: 
     
 3-5 ml / kg BW / h 0.9 % saline i.v. for 3 hours 
 
 
 
 
  Intra-arterial angiography / angioplasty: 
   
day  0   Laboratory values: urinary NGAL 4-6 hours following CM application 
 
 
 
 
                           urinary NGAL normal            urinary NGAL elevated 
 
 
 
 
      
                       Randomization 
 
 
 
                                   3-4 ml / kg BW / h
               Unrestricted oral fluid intake             0.9% saline i.v. for
                                   6 hours 
 
 
 
 
 
days +1,+2  Laboratory values: Creatinine, complete blood count, etc. 
 
Figure 1 Scheme for ANTI-CIN Study.
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￿ Patients with life-threatening underlying disease
￿ Contraindication for volume therapy
￿ Pregnancy
￿ CM application within 7 days prior to intervention
Standardized procedure
Hospitalized patients scheduled for elective intra-arterial
angiography will be prepared for CM application using a
weight-based hydration protocol.
Monomeric Iomeron
® (iomeprol, Bracco Austria,
Vienna) will be used exclusively as contrast media. Blood
samples for standard evaluation, including serum creati-
nine and cystatin C, will be drawn at baseline and after
24 and 48 hours from all patients. A BW/h saline infu-
sion (3-5 ml/kg) will be given for 3 hours before CM
application. Urine samples for NGAL testing will be col-
lected shortly before (baseline) and after 4 to 6 hours fol-
lowing CM application. NGAL will be measured with the
commercially available ARCHITECT
® NGAL Test,
Abbott Laboratories, Abbott Park, Illinois, U.S.A. [15,39].
Patients who develop CIN will be treated and followed
at the Division of Nephrology and Hemodialysis accord-
ing to established standards.
Randomization
Patients will be allocated randomly using a Web-based
computer program http://www.randomizer.at. Balance of
treatment counts is achieved by the biased-coin method
with probability 0.7 [40]. Randomization will occur
shortly after receipt of the second urinary NGAL value.
NGAL determinations will be made by the medical
technical staff of the Clinical Institute for Laboratory
Medicine, Medical University of Graz, Austria. The cri-
teria for randomization (after 2
nd NGAL testing, 4 -6
hours following CM application) are:
￿ Patients with NGAL levels > 150 ng/ml, if baseline
was below 75 ng/ml [23].
￿ Patients with doubling of NGAL values, if baseline
values were > 75 ng/ml [18].
Procedure following randomization
Study patients with a defined increase of urinary NGAL
values at 4 to 6 hours after CM application will be ran-
domized into one of two groups:
Patients of Group A will receive 3-4 ml/kg BW/h
0.9% saline intravenously for 6 hours post procedure in
addition to oral fluid.
Patients of Group B will receive unrestricted oral
fluid. An intake of at least 500 ml tea or water is advised
and provided on the ward.
Blinding
Blinding of investigators and patients is not feasible as it
is immediately recognizable and impossible to conceal
that only one group (Group A) receives saline
intravenously.
Outcome measures
Primary outcome measure
CIN defined by an increase greater than 25% of baseline
serum creatinine. Additionally, patients will be classified
according to the Cockcroft and Gault, as well as the
MDRD and the CKD-EPI calculation formula.
Secondary outcome measures
Urinary NGAL values, cystatin C values, contrast media
associated changes of cardiac parameters such as NT-
pro-BNP/Troponin T, changes in urinary cytology, need
for renal replacement treatment, length of hospital stay
and death.
Monitoring for adverse events
The study investigators and the Coordination Center for
Clinical Studies, Medical University of Graz, authored a
standardized operating procedure for reporting adverse
events. Although this trial has not been declared as a
pharmacological interventional study, because the
volume expansion is considered a physical rather than a
pharmacological effect, the investigators voluntarily
chose to report adverse events according to the guide-
lines for a pharmacological interventional study. All
relevant adverse events will be summarized and reported
to the Ethics Committee of the Medical University of
Graz.
Data collection
Historical data will be obtained from the patient or col-
lected from medical records. These include age, gender,
weight, height, relevant co-morbidities, existence of per-
ipheral edema, current medication, contrast media dose
and location of angiography/angioplasty/stent implanta-
tion. Furthermore, there will be repeated lab studies
including complete blood count, electrolytes, serum
creatinine, coagulation profile, liver function test, C-
reactive protein, bicarbonate and spot urine analysis and
urinary NGAL. Length of hospitalization will documen-
ted. All data are stored in an electronic case report
form.
Sample size calculations
Sample Size: Alpha = 0.05, power = 0.8, two-sided test.
Assuming a clinically relevant difference in CIN inci-
dence of 20% and 60% CIN in the control group (worst
case), 108 patients per group are required for the chi
square test. Only patients who meet the NGAL criteria
for randomization will be included. We assume that
20% of the included patients, which would amount to
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groups. If fewer than 48 patients are randomized after
the inclusion of 240 patients, the NGAL criteria for ran-
domization will be adapted in order to meet the objec-
tive of including not more than 1200 patients.
Recruitment will continue until 240 patients have been
randomized.
Analysis: Chi square tests will be used for CIN reduc-
tion. Wilcoxon’s rank sum test will be applied to contin-
uous measurements.
Statistical considerations
The diagnostic value of a two-point-measurement of
NGAL, cystatin C and creatinine before and after CM
application, as compared to a single-point-measurement
only after CM application with respect to CIN will be
assessed through receiver operating characteristic (ROC)
within the patients who received standard therapy. The
analysis has to account for the bias that is caused by the
exclusion of patients who receive treatment A from
ROC analysis on the condition of an elevated NGAL.
The available sample size for ROC analysis is deter-
mined by the number of patients, the incidence of CIN
and the number of patients who receive treatment A.
We assume that 20% of the included patients will
develop CIN.
Data analysis
Treatments will be compared according to relative
change of creatinine from baseline by the Wilcoxon test
and Pearson’s chi square test (two-sided, alpha = 0.05).
As mentioned above, those patients without a relevant
increase of NGAL will also be followed. This will allow
us to retrospectively calculate sensitivity and specificity
of NGAL testing for CIN.
Discussion
To the best of our knowledge there is no other interven-
tional study published or ongoing using “timesaving”
effect due to NGAL evaluation to prevent CIN http://
www.clinicaltrials.gov.
Though a controlled study evaluating the benefit of
early diagnosis and intervention would be highly desir-
able, the planning of such a study has some major diffi-
culties and drawbacks:
1. An established cut-off for NGAL has not been
defined for patients with CKD. Many investigators have
found a wide range from approximately 5 to 800 ng/ml
in such patients. We therefore believe that at present,
one single-point measurement may be insufficient to
differentiate between acute and chronic disease and so
will perform 2-point measurements. It is hoped that
inter-individual changes before and after investigation
will be of great help in this differentiation.
2. As an increase of NGAL after cardiopulmonary
bypass in children (without pre-existing renal disease or
nephrosclerosis) has been found without development of
A K I ,am i l di n c r e a s eo fN G A Lv a l u e sw i l ln o tl e a dt o
randomization [15].
3. Since increased baseline values above the estab-
lished cut-off for AKI should not lead to exclusion from
the study of patients with CKD, we have developed
subtle criteria for randomization. It is our hypothesis
that at least doubling of NGAL should be demanded in
patients with CKD, whereas in patients with very low
values at baseline even a higher-fold increase might be
without clinical relevance, as long as values stay below
150 ng/ml.
4. To define study size and patient numbers it would
be necessary to know the percentage of patients who
will show NGAL increase. In such a high-risk patient
group, we would estimate that more than 15 to 20 per-
cent of patients might develop CIN, based on the con-
trast media literature. A fine-tuning of cut-off levels
after intermediate analysis would be statistically possible
without patient exclusions.
5. The effect of intensified hydration is not clearly
established, although data support its benefit.
6. Urinary NGAL seems to be even better than plasma
NGAL. The Architect kit showed reliable results [15].
In summary, a clearly defined and simplified prophy-
lactic volume expansion strategy showing a benefit of
earlier intervention in patients with markedly elevated
urinary NGAL values, indicating CIN, might arise from
the data this study produces.
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